
Opinion|Videos|January 17, 2025
Integrating Emerging BTKi Therapies Into Current Treatment Guidelines
Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.
Advertisement
Video content above is prompted by the following:
- What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the MCL landscape?
- In the context of the evolving treatment landscape, how do you envision the integration of emerging BTKi therapies impacting current treatment guidelines for CLL and MCL? What factors should be considered?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5